CAS: 575-04-2; 7-Methoxy-4-(Trifluoromethyl)-2H-Chromen-2-One

该化合物是属于科马林家族的合成有机化合物,其特点是苯丙胺结构;该化合物的特点是7位置的甲氧基化合物(-OCH3)和4位置的科马林环(-CF3)三氟甲基化合物(-CF3),该物质对其化学特性和再活性有重大影响;该物质通常是一种固体或晶状物质,因其荧光特性而闻名,因此在各种应用中有用,包括作为生物化学实验中的荧光探针;三氟甲基化合物的存在增强了其脂性与稳定性,而甲氧氧基化合物组则可能影响其在有机溶剂中的溶解性;此外,7-甲基苯氧基-4-(三氟甲基)丙胺可能会显示出生物活动,包括抗微生物和抗癌特性,这是医学化学研究的主题.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

7-hydroxy-4-(trifluoromethyl)-2H-chromen-2-one methyl iodide dimethyl sulfate 7-hydroxy-4-(trifluoromethyl)-2H-chromen-2-one

合成工艺路线路线简述

  • 合成目标产物 7-Methoxy-4-(Trifluoromethyl)Coumarin 主要起始原料 7-Hydroxy-4-(Trifluoromethyl)Coumarin And Dimethyl Sulfate
  • (文献来源)合成步骤主要原料 7-Hydroxy-4-(Trifluoromethyl)Coumarin 和 Dimethyl Sulfate
📜5-Methoxy-2-Trifluoroacetylphenol置于吡啶,Chromium(Vi) Oxide,Sodium Hydride体系中,用 乙醚,二氯甲烷 作为反应溶剂,化学反应 40.0H,反应生成 7-甲氧基-4-(三氟甲基)香豆素
参考文献:2-(三氟乙酰基)苯酚与乙烯基三苯基氯化鏻反应合成4-三氟甲基-2H-色烯
标题:2-(三氟乙酰基)苯酚与乙烯基三苯基氯化鏻反应合成4-三氟甲基-2H-色烯
摘要:根据 Schweizer 协议,在苯环上取代的 4-Cf 3-2 H-色烯由取代的 2-(三氟乙酰基)苯酚和乙烯基三苯基氯化鏻以中等至优异的产率制备.研究了芳环取代基的类型和位置对4-Cf 3-2 H-色烯收率的影响.已经表明4-Cf 3-2 H-色烯是4-Cf 3-香豆素的方便前体.
DOI:10.1039/d2Ob01177H

海关参考信息

专利信息


专利号:US-11091445-B2
优先权日:2016-10-24
标题 :Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
发明人:RUCH WERNECK GUIMARÃES CRISTIANO; FELYPE ZANETI DE AZEVEDO HATYLAS; MASCARELLO ALESSANDRA; WATANABE DA COSTA RENATA; FREIRE TORRES RUSSO VALTER; MANNOCHIO DE SOUZA RUSSO ELISA
权利人:ACHE LABORATORIOS FARMACEUTICOS SA
摘要:The present disclosure relates to novel and inventive pharmacologically active benzimidazole derivative compounds, which surprisingly have high affinity for melatonin MT1 and MT2 receptors and low affinity for CYP450 complex enzymes, specially CYP1A2. The present invention also relates to novel and inventive routes of synthesis of these compounds, pharmaceutical compositions comprising the compounds and the use of these compounds in the treatment of individuals affected by psychiatric disorders and/or sleep disorders related to these receptors (specially depression, anxiety, circadian cycle disorders), in addition to a process for producing the composition.

专利号:SA-109300715-B1
优先权日:2008-12-01
标 题 :Synthesis of (R)-3-((E)-2-(pyrrolidine-3-yl)-phenyl)-5-(tetrahydropyrane-4-yloxy)pyridine and forms new salts thereof

专利号:US-8633227-B2
优先权日:2008-12-01
标 题 :Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine
发明人:AKIREDDY SRINIVASA RAO; BREINING SCOTT R; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; GATTO GREGORY J; GENUS JOHN; HAMMOND PHILIP S; MITCHENER JR JOESPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT; YOHANNES DANIEL; FEDOROV NIKOLAI
权利人:AKIREDDY SRINIVASA RAO; BREINING SCOTT R; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; GATTO GREGORY J; GENUS JOHN; HAMMOND PHILIP S; MITCHENER JR JOESPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT; YOHANNES DANIEL; FEDOROV NIKOLAI; TARGACEPT INC
摘要:The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.

专利号:CA-2744197-A1
优先权日:2008-12-01
标 题 :Synthesis and novel salt forms of (r)-3-((e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine

专利号:US-2012015983-A1
优先权日:2008-12-01
标 题 :Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine

专利号:US-2014107163-A1
优先权日:2008-12-01
标题:Synthesis and novel salt forms of (r)-3-((e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Santes-Palacios R, Olguín-Reyes S, Hernández-Ojeda SL, Camacho-Carranza R, Espinosa-Aguirre JJ. Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity. Toxicol In Vitro. 2020 Dec;69:105009. doi: 10.1016/j.tiv.2020.105009. Epub 2020 Sep 29. 89(4):435-45. doi: 10.1124/mol.115.102111. Epub 2016 Jan 29.
3: Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol. 2014 Sep;66(9):1339-46. doi: 10.1111/jphp.12259. Epub 2014 Apr 15. 279(9):1607-20. doi: 10.1111/j.1742-4658.2011.08411.x. Epub 2011 Nov 25.
5: Makaji E, Trambitas CS, Shen P, Holloway AC, Crankshaw DJ. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms. Toxicol Sci. 2010 Feb;113(2):293-304. doi: 10.1093/toxsci/kfp255. Epub 2009 Oct 25. 283(31):21808-16. doi: 10.1074/jbc.M708582200. Epub 2008 May 21.

合成参考文献


摘要:S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知